|
Avelumab Clinical Trials
10 actively recruiting trials across 5 locations
▼ -2 trials since August 2026
Also known as: Anti-PD-L1, BAVENCIO, BAVENCIO®, Bavencio, MSB 0010718C +2 more
Pipeline
Phase 2: 8Phase 1/2: 2
Top Sponsors
- Ulrik Lassen1
- Queen Mary University of London1
- Panagiotis Konstantinopoulos, MD, PhD1
- National Cancer Institute (NCI)1
- NRG Oncology1
Indications
- Cancer10
- Lung Cancer2
- High Grade Neuroendocrine Tumors of the Urinary Tract1
- Small Cell Carcinoma of the Bladder1
- Neoplasia1
Other5 trials
Birmingham, Alabama1 trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
University of Alabama at Birmingham Cancer Center
Phase 2
Washington D.C., District of Columbia1 trial
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Georgetown University
Phase 2
Miami, Florida1 trial
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Sylvester Comprehensive Cancer Center - Miami
Phase 1/2
Bethesda, Maryland1 trial
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Institutes of Health Clinical Center
Phase 2
Boston, Massachusetts1 trial
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.